RA Capital Management’s Post

Founders often get crushed by dilution when raising a Series A. Dilution is a product of capital raised and company valuation. Curie.Bio helps founders minimize dilution by maximizing progress with less capital. By reaching critical milestones on blockbuster TPPs, you can raise more capital at a much higher valuation. Last fall, our first portfolio company, Forward Therapeutics, Inc., raised a $50M Series A to generate clinic data. A recent Oppenheimer report revealed this raise was the BIGGEST valuation step up compared to all other therapeutics companies that raised a Series A in the last 12 months. The best part? The founders retained significant ownership in their company. That's the power of the Curie.Bio model. That's how we #freethefounders. If you have an exciting therapeutic idea, we'd love to collaborate. Contact our team or visit our website. https://lnkd.in/e4NWnqwF

Attovia Therapeutics announced the closing of a $105 million oversubscribed Series B financing, led by Goldman Sachs, with participation from new investors Cormorant Asset Management, Nextech Ventures, Redmile Group, EcoR1 Capital, LLC, Marshall Wace, and Logos Capital. The total capital raised by the Company since its launch in June 2023 to $165 million. Factacy.ai Congratulations and wishes them well as the proceeds from the financing will be used to advance the Companys lead programs ATTO-1310 and ATTO-002 through initial clinical data readouts, expand the Companys immunology and inflammation pipeline, and to further develop the ATTOBODY platform. Redmile Group, Cormorant Asset Management, LP, Marshall Wace EcoR1 Capital, LLC, Frazier Life Sciences, Goldman Sachs Nextech Ventures, LOGOS CAPITAL, venBio, Illumina Ventures, Factacy.ai Tao Fu #funding #fundraising #seriesB

One of the biotech industry's star investors, the 38-year-old VC firm ARCH Venture Partners, uncorked its 13th fund on Thursday. The Chicago-based firm has another $3 billion to deploy into its large bets on neuroscience, AI, obesity, autoimmune diseases and other areas ripe for more precise treatments. “We’re trying to slow down, but not slowing down because there’s so much cool stuff right now,” managing director Bob Nelsen said Wednesday in an interview with Endpoints News. “Every time we think we’re going to slow down, AI happens or some other thing happens, so it’s an amazing environment to start companies, small ones or big ones, and we do both.” The firm has dished out larger checks and created more startups than most other biotech VC investors over the years. Its current roster includes Xaira Therapeutics, Mirador Therapeutics, Seaport Therapeutics and Metsera among dozens of others. “I’m very hopeful over the next 10 years, and certainly the life of Fund XIII, that we’ll continue to evolve the precision medicine models so that we can better serve patients with lupus, with rheumatoid arthritis, with metabolic disease, cardiovascular disease,” managing director Kristina Burow said in an interview. “Those aren’t just giant, lump diseases. We’re going to start to be able to parse different patients into different medicines.” #biotech #venturecapital #arch #biotechvc #vcfirm #lifesciences

San Francisco-based Foresite Capital ,led by founder and CEO Jim Tananbaum has closed its sixth fund with $900 million in capital commitments, emphasizing its dedication to advancing healthcare and life sciences technologies. Fund VI has attracted a diverse group of global investors, reflecting strong confidence in Foresite Capital's strategy. The firm will focus on precision therapeutics, life science infrastructure, and healthcare delivery. Founded in 2011, Foresite Capital manages over $3.5 billion in assets and has a notable track record, including 47 IPOs and 58 FDA-approved drugs. The fund's portfolio features promising companies like Alumis and CG Oncology. #ForesiteCapital #HealthcareInvestment #LifeSciences #PrecisionTherapeutics #BiotechInnovation #InvestmentFund #HealthcareDelivery #VentureCapital #FundVI #BiotechInvesting #startup77

YPOG advised lead investor Vesalius Biocapital IV on the Series C financing round of HepaRegeniX GmbH. Existing investors such as Novo Holdings, Boehringer Ingelheim Venture Fund, and HTGF | High-Tech Gründerfonds also participated in the investment.   The new funding will support the Phases Ib/ IIa clinical trial focused on improving liver healing and preventing liver failure.   Congratulations to our client Vesalius and all parties involved!   The YPOG team was led by Martin Schaper and included Dr. Lutz Schreiber, Benjamin Müller, Matthias Treude as well as Cyra Dittberner.   ➡ Link to the press release in the comments below.   #YPOG #PartnersOfGamechangers #VentureCapital #Growth #Funds #Transactions

The private equity manager TPG said Tuesday morning it closed a $580 million “Life Sciences Innovations” fund that will invest in about 15 to 20 companies. The new fund follows a $650 million fund at Goldman Sachs, a $500 million-plus fund at J.P. Morgan and about two dozen funds from biotech and life sciences specialists so far this year... ....Ng said in a statement that most of the fund’s capital will go into “preclinical and clinical-stage therapeutics companies.” Therapeutic areas can include oncology, I&I, cardiometabolic, ophthalmology and rare diseases. .... #biotech #biotechnology #lifescience #lifesciences #celltherapy #genetherapy #advancedtherapies #regenerativemedicine #funding #financing #earlystage #preclinicalfunding #clinicaltrials #clinicalstage #fundinggrowth #pipelinefunding #580m

Thrilled by Eurazeo’s H1 successes we had the pleasure to present with William Kadouch-Chassaing.   Our H1 results reflected the successful execution of our strategic plan in line with our medium-term objectives presented to the market in November 2023. We reported a dynamic growth in asset management with a strong momentum in fundraising up +63% with €2.1bn raised in H1 2024, including €453M from private clients. We also increased realizations, including Amolyt Pharma (Biotech), Onfido (Venture), LumApps (Growth), EFESO Management Consultants, DORC Dutch Ophthalmic Research Center (International), Peters Surgical, and I-TRACING.   We warmly thank our more than 400 great talents, as well as our clients, investors, entrepreneurs and shareholders for their trust and support in the implementation of our strategic roadmap.   🔎 Read more: https://lnkd.in/eY89RySe   #PrivateEquity #AssetManagement #MidMarket #Growth #Impact #strategy #PowerBetterGrowth #results #finance

🦾 Our Army Of 5,000 Shareholders Is Growing By The Day... Discover how our army of loyal Cytonics Corporation shareholders is propelling us towards revolutionizing regenerative medicine! 🖇 invest.cytonics.com 💸 Fundraising Triumphs: A Collective Achievement To date, we have raised over $25M in pursuit of developing the first and only therapy for osteoarthritis. This monumental effort boasts: ➡️ A $4M investment from Synthes (a medical device company acquired by Johnson and Johnson for $19B), alongside ➡️ $10M raised through equity crowdfunding, with ➡️ Over 100 orthopedic surgeons who utilize our APIC therapy for osteoarthritis and understand the significance of our drug development program. Our Cytonics family has expanded to over 5,000 shareholders who have played a pivotal role in our success through repeat investment, an outpouring of encouragement, and spreading the word. Every investor, regardless of the size of their committment, is a part of our family and treated as such. The current round has welcomed over 1,100 new shareholders, many of whom are placing their first equity crowdfunding investment (292 to be exact)! 🔍 A Closer Look Into Our Campaign The unwavering loyalty and commitment of our shareholders is a testament to the deep trust and shared goals that bind us. This round alone has raised over $2.7M from more than 1,100 investors, 60% of whom are returning shareholders. This remarkable rate of recurring investment is not just a metric of success but a beacon of the belief in our mission, confidence in management, and the impact of our research. ❤️ In Gratitude Your continued support and belief in Cytonics are more than just a financial decision; you are the driving force behind our relentless pursuit of improving human well-being. It's a shared journey towards creating long-term value and making a significant impact on the lives of those affected by osteoarthritis. #biotechnology #arthritis #investing #crowdfunding #venturecapital #healthcare #drugdevelopment #clinicaltrials #regenerativemedicine

Life sciences VC Francesco De Rubertis hints at a wave of upcoming IPOs, fueled by increased secondary stock offerings. Keep an eye on this space for a parade of new public biotech firms despite market swings. Remember CG Oncology's standout IPO? More poised to follow. Watch for a season of innovation and smart investing ahead! 🚀 #Biotech #InvestmentTrend #SummerHeat

🦾 Our Army Of 5,000 Shareholders Is Growing By The Day... Discover how our army of loyal Cytonics Corporation shareholders is propelling us towards revolutionizing regenerative medicine! 🖇 invest.cytonics.com 💸 Fundraising Triumphs: A Collective Achievement To date, we have raised over $25M in pursuit of developing the first and only therapy for osteoarthritis. This monumental effort boasts: ➡️ A $4M investment from Synthes (a medical device company acquired by Johnson and Johnson for $19B), alongside ➡️ $10M raised through equity crowdfunding, with ➡️ Over 100 orthopedic surgeons who utilize our APIC therapy for osteoarthritis and understand the significance of our drug development program. Our Cytonics family has expanded to over 5,000 shareholders who have played a pivotal role in our success through repeat investment, an outpouring of encouragement, and spreading the word. Every investor, regardless of the size of their committment, is a part of our family and treated as such. The current round has welcomed over 1,100 new shareholders, many of whom are placing their first equity crowdfunding investment (292 to be exact)! 🔍 A Closer Look Into Our Campaign The unwavering loyalty and commitment of our shareholders is a testament to the deep trust and shared goals that bind us. This round alone has raised over $2.7M from more than 1,100 investors, 60% of whom are returning shareholders. This remarkable rate of recurring investment is not just a metric of success but a beacon of the belief in our mission, confidence in management, and the impact of our research. ❤️ In Gratitude Your continued support and belief in Cytonics are more than just a financial decision; you are the driving force behind our relentless pursuit of improving human well-being. It's a shared journey towards creating long-term value and making a significant impact on the lives of those affected by osteoarthritis. #biotechnology #arthritis #investing #crowdfunding #venturecapital #healthcare #drugdevelopment #clinicaltrials #regenerativemedicine